Background: Mitochondria have emerged as a major target for anticancer therapy because of their critical role in cancer cell survival. Our preliminary works have suggested that dihydroergotamine tartrate (DHE), an antimigraine agent, may have effects on mitochondria. Methods: We examined the effect of DHE on the survival of several lung cancer cells and confirmed that DHE suppressed diverse lung cancer cell growth effectively. To confirm whether such effects of DHE would be associated with mitochondria, A549 cells were employed for the evaluation of several important parameters, such as membrane potential, reactive oxygen species (ROS) generation, apoptosis, ATP production and autophagy. Results: DHE decreased membrane permeability, increased ROS generation as well as apoptosis, and disturbed ATP production. Eventually, mitophagy was activated for damaged mitochondria. Conclusion: Taken together, our findings demonstrate that DHE induces lung cancer cell death by the induction of apoptosis and mitophagy, thus suggesting that DHE can be developed as an anti-lung cancer therapeutic agent.

1.
Rothlin E: Historical development of the ergot therapy of migraine. Int Arch Allergy Appl Immunol 1955;7:205-209.
2.
Silberstein SD: The pharmacology of ergotamine and dihydroergotamine. Headache 1997;37:S15-S25.
3.
Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L: Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol 2003;140:277-284.
4.
Bevan JA, Brayden JE: Nonadrenergic neural vaspdilator mechanisms. Circ Res 1987;60:309-326.
5.
Roquebert J, Grenié B: Alpha 2-adrenergic agonist and alpha 1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch Int Pharmacodyn Ther 1986;284:30-37.
6.
Don AS, Hogg PJ: Mitochondria as cancer drug targets. Trends Mol Med 2004;10:372-378.
7.
Tiwari BS, Belenghi B, Levine A: Oxidative stress increased respiration and generation of reactive oxygen species, resulting in ATP depletion, opening of mitochondrial permeability transition, and programmed cell death. Plant Physiol 2002;128:1271-1281.
8.
Narendra DP, Youle RJ: Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid Redox Signal 2011;14:1929-1938.
9.
Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ: Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 2010;191:933-942.
10.
Narendra D, Tanaka A, Suen DF, Youle RJ: Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008;183:795-803.
11.
Leist M, Single B, Naumann H, Fava E, Simon B, Kühnle S, Nicotera P: Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun 1999;258:215-221.
12.
Gallagher RM: Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53:1285-1291.
13.
Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, Saper J, Hoffert M, Vogel B, Holtz N: Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447-453.
14.
Chang SH, Kim JE, Lee JH, Minai-Tehrani A, Han K, Chae C, Cho YH, Yun JH, Park K, Kim YS, Cho MH: Aerosol delivery of eukaryotic translation initiation factor 4E-binding protein 1 effectively suppresses lung tumorigenesis in K-rasLA1 mice. Cancer Gene Ther 2013;20:331-335.
15.
Minai-Tehrani A, Chang SH, Kwon JT, Hwang SK, Kim JE, Shin JY, Yu KN, Park SJ, Jiang HL, Kim JH, Hong SH, Kang B, Kim D, Chae CH, Lee KH, Beck GR Jr, Cho MH: Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice. Cell Oncol 2013;36:15-26.
16.
Yu KN, Minai-Tehrani A, Chang SH, Hwang SK, Hong SH, Kim JE, Shin JY, Park SJ, Kim JH, Kwon JT, Jiang HL, Kang B, Kim D, Chae CH, Lee KH, Yoon TJ, Beck GR Jr, Cho MH: Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS One 2010;5:e15623.
17.
Hwang SK, Lim HT, Minai-Tehrani A, Lee ES, Park J, Park SB, Beck GR Jr, Cho MH: Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice. Am J Respir Crit Care Med 2009;179:1131-1140.
18.
Hwang SK, Kwon JT, Park SJ, Chang SH, Lee ES, Chung YS, Beck GR Jr, Lee KH, Piao L, Park J, Cho MH: Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther 2007;14:1721-1730.
19.
Herbst RS, Sandler AB: Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 2004;9:S19-S26.
20.
Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D: Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2015;121:883-892.
21.
Akita RW, Sliwkowski MX: Preclinical studies with erlotinib (Tarceva). Semin Oncol 2003;30(suppl 7):15-24.
22.
Hirsh V: Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011;7:817-825.
23.
Fiala O, Pesek M, Finek J, Krejci J, Benesova Z: Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy. Neoplasma 2013;60:129-134.
24.
D'Souza GG, Wagle MA, Saxena V, Shah A: Approaches for targeting mitochondria in cancer therapy. Biochim Biophys Acta 2011;1807:689-696.
25.
Luo KW, Sun JG, Chan JY, Yang L, Wu SH, Fung KP, Liu FY: Anticancer effects of imperatorin isolated from Angelica dahurica: induction of apoptosis in HepG2 cells through both death-receptor- and mitochondria-mediated pathways. Chemotherapy 2011;57:449-459.
26.
Gulbins E, Dreschers S, Bock J: Role of mitochondria in apoptosis. Exp Physiol 2003;88:85-90.
27.
Waterhouse NJ, Goldstein JC, Kluck RM, Newmeyer DD, Green DR: The (Holey) study of mitochondria in apoptosis. Methods Cell Biol 2001;66:365-391.
28.
Edinger AL, Thompson CB: Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004;16:663-669.
29.
Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
30.
Okatsu K, Oka T, Iguchi M, Imamura K, Kosako H, Tani N, Kimura M, Go E, Koyano F, Funayama M, Shiba-Fukushima K, Sato S, Shimizu H, Fukunaga Y, Taniguchi H, Komatsu M, Hattori N, Mihara K, Tanaka K, Matsuda N: PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun 2012;3:1016.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.